Legacy Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Legacy Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,086	Closed	-$231K	–	438
2026 Q1	$231K	Buy	4,086 +353	+9%	+$20.6K	0.03%	372
2025 Q4	$222K	Buy	+3,733	New	+$203K	0.03%	369
2019 Q2	–	Sell	-162	Closed	-$14K	–	219
2019 Q1	$14K	Buy	162 +93	+135%	+$8.62K	﹤0.01%	534
2018 Q4	$6K	Hold	69	–	–	﹤0.01%	687
2018 Q3	$6K	Hold	69	–	–	﹤0.01%	636
2018 Q2	$7K	Hold	69	–	–	﹤0.01%	616
2018 Q1	$5K	Hold	69	–	–	﹤0.01%	622
2017 Q4	$6K	Buy	+69	New	+$6K	﹤0.01%	592

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Legacy Financial Advisors's BMRN Position: Q2 2026 in Review

Legacy Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4,086 shares — an estimated $231K sold.

Legacy Financial Advisors first reported a position in BMRN in Q4 2017 and held it in 8 quarters. The position peaked at $231K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Legacy Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Legacy Financial Advisors sold 4,086 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $231K.
Legacy Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Legacy Financial Advisors's BioMarin Pharmaceuticals position peaked at $231K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Legacy Financial Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.